Cline Scientific publishes company description introducing listing on Nasdaq First North Growth Market
Cline Scientific AB (publ) (“Cline” or “the Company”) received a conditional approval for admission to trading of the Company's shares on the Nasdaq First North Growth Market (“Nasdaq First North”) on 28 May 2021. For this reason, the company has published a company description on its website in accordance with Nasdaq First North Growth Markets' listing requirements.
The company description can be found on the Company's website clinescientific.com/s/Cline_company_description_2021.pdf.
The company description does not constitute a prospectus, has not been approved by the Swedish Financial Supervisory Authority and does not contain an offer to subscribe for the Company's shares or other financial instruments in Sweden or in any other jurisdiction. The company description includes, but is not limited to, information about the company's operations, market, financial position, risks and information about the board, management and corporate governance.
For more information, please contact:
Patrik Sundh, CEO
Phone: +46 703-585 088
Cline Scientific AB (publ) Phone: 031-387 55 55
Argongatan 2 C Email: email@example.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase